1. Home
  2. MNPR vs SCM Comparison

MNPR vs SCM Comparison

Compare MNPR & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$61.53

Market Cap

403.4M

Sector

Health Care

ML Signal

HOLD

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$8.71

Market Cap

397.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNPR
SCM
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
403.4M
397.8M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
MNPR
SCM
Price
$61.53
$8.71
Analyst Decision
Strong Buy
Hold
Analyst Count
13
1
Target Price
$101.42
$9.00
AVG Volume (30 Days)
145.1K
305.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
15.50%
EPS Growth
N/A
N/A
EPS
N/A
0.95
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$9.23
Revenue Growth
N/A
N/A
52 Week Low
$26.06
$8.55
52 Week High
$105.00
$15.39

Technical Indicators

Market Signals
Indicator
MNPR
SCM
Relative Strength Index (RSI) 58.07 18.69
Support Level $50.92 N/A
Resistance Level $89.51 $12.40
Average True Range (ATR) 3.09 0.38
MACD 1.10 -0.08
Stochastic Oscillator 91.62 13.15

Price Performance

Historical Comparison
MNPR
SCM

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Share on Social Networks: